Athira Pharma, Inc. — Director's Dealing 2021

Jan 9, 2021

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2020-12-31

Reporting Person: Romano Kelly A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-22	Common Stock	L	315	$31.7431	Acquired	315	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$29.41	2030-12-10	Common Stock (27742)	27742	Direct

Footnotes

F1: The acquisition of these derivative securities was previously reported on the Reporting Person's Form 4 filed on December 14, 2020. This holding is included solely to reconfirm the number of derivative securities of this class beneficially owned by the Reporting Person.

F2: One-thirty-sixth of the shares subject to the option will vest on January 11, 2021 and thereafter one-thirty-sixth of the shares subject to the option will vest each month thereafter.